No overview information available.
No background information available.
用于控制原发性癫痫病人的痉挛症状,预防并治疗神经外科手术中的惊厥发作。
No associated conditions information available.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|
No clinical trials found for this drug
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
---|---|---|---|---|---|
Pfizer Laboratories Div Pfizer Inc | INTRAVENOUS, INTRAMUSCULAR | 50 mg in 1 mL | 2022/05/10 | 0069-5471 | |
INTRAMUSCULAR, INTRAVENOUS | 50 mg in 1 mL | 2023/02/23 | 0641-6136 | ||
INTRAMUSCULAR, INTRAVENOUS | 50 mg in 1 mL | 2022/07/25 | 70121-1390 | ||
INTRAMUSCULAR, INTRAVENOUS | 50 mg in 1 mL | 2022/05/01 | 63323-403 | ||
INTRAMUSCULAR, INTRAVENOUS | 50 mg in 1 mL | 2022/07/25 | 70121-1381 | ||
INTRAMUSCULAR, INTRAVENOUS | 50 mg in 1 mL | 2022/12/29 | 64679-730 | ||
INTRAVENOUS, INTRAMUSCULAR | 50 mg in 1 mL | 2023/11/08 | 68462-622 | ||
INTRAVENOUS, INTRAMUSCULAR | 50 mg in 1 mL | 2023/11/08 | 68462-621 | ||
INTRAMUSCULAR, INTRAVENOUS | 50 mg in 1 mL | 2023/12/18 | 65162-998 | ||
INTRAMUSCULAR, INTRAVENOUS | 50 mg in 1 mL | 2023/12/18 | 65162-999 |
Medicine Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
---|
No EMA products found for this drug
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval No. |
---|
No HSA products found for this drug
Product Name | Approval No. | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
---|---|---|---|---|---|---|---|---|---|
国药准字H20233274 | 注射剂 | N/A | 2ml:100mg(按C₁₅H₁₁N₂NaO₂计) | Chemical Drug | Approved | 2023/03/15 | Domestic | ||
国药准字H20233275 | 注射剂 | N/A | 10ml:500mg(按C₁₅H₁₁N₂NaO₂计) | Chemical Drug | Approved | 2023/03/15 | Domestic |
Product Name | Registration Code | Company | Category | Sale Type | Reg. Date |
---|
No PPB products found for this drug
Product Name | ARTG ID | Sponsor | Status | Reg. Date | Ingredient |
---|
No TGA products found for this drug